Cargando…
IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes
Autores principales: | de Melo Campos, Paula, Machado-Neto, João Agostinho, Lorand-Metze, Irene, Costa, Fernando Ferreira, Olalla Saad, Sara Teresinha, Traina, Fabiola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003099/ https://www.ncbi.nlm.nih.gov/pubmed/29519376 http://dx.doi.org/10.1016/j.bjhh.2017.10.001 |
Ejemplares similares
-
Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else
por: de Melo Campos, Paula, et al.
Publicado: (2014) -
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes
por: Machado-Neto, João Agostinho, et al.
Publicado: (2011) -
Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms
por: Scopim-Ribeiro, Renata, et al.
Publicado: (2016) -
Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015) -
Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2015)